



Research Article

ESTIMATION OF GEMCITABINE-INDUCED LIPID PEROXIDATION USING COMMON LABORATORY MARKERS: ROLE OF MORIN

Sarbani Dey Ray *

Department of Pharmaceutical Sciences, Assam University, Silchar, India

*Corresponding Author Email: sarbanideyray09@gmail.com

Article Received on: 29/05/18 Approved for publication: 15/06/18

DOI: 10.7897/2230-8407.096105

ABSTRACT

The objective of the present *in vitro* study was to explore antiperoxidative potential of morin on gemcitabine-induced lipid peroxidation. Goat liver tissue homogenate was used as source of lipid. Two common laboratory markers such as malondialdehyde and reduced glutathione were used for the model. The results showed that gemcitabine has the ability to induce lipid peroxidation to a significant extent and it was also found that morin has the ability to suppress the gemcitabine-induced toxicity.

Keywords: Gemcitabine, morin, lipid peroxidation, malondialdehyde, reduced glutathione

INTRODUCTION

Morin (3, 5, 7, 2', 4'-pentahydroxyflavone), belongs to the member of flavonols. Several studies showed the antioxidant potential of morin on drug induced lipid peroxidation. It was found that morin exert beneficial effect on busulfan and paclitaxel-induced lipid peroxidation^{1,2}. Gemcitabine falls under the class of antimetabolites.

Chemically it is a pyrimidine nucleoside prodrug. Gemcitabine has wide application in cancer therapy particularly breast cancer, ovarian cancer, non-small cell lung cancer, pancreatic cancer and bladder cancer. But along with its use the compound also produces several side effects such as pale skin, easy bruising or bleeding, numbness or tingling feeling, weakness, nausea, vomiting, upset stomach, diarrhea, constipation, headache, skin rash, drowsiness, hair loss etc³. Lipid peroxidation is a free radical related process that may occur in the biological system under enzymatic control or non-enzymatically⁴⁻⁶. The cytotoxic end products of lipid peroxidation are mainly aldehydes as exemplified by malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE) etc⁷. It was reported that resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model⁸.

In another study Gemcitabine showed improved efficacy when used along with vitamin E⁹. In view of the above findings, the present work has been carried out *in vitro* to evaluate the antiperoxidative potential of morin on gemcitabine-induced lipid peroxidation.

MATERIALS AND METHODS

Thiobarbituric acid (TBA) and trichloroacetic acid (TCA) were purchased from Ranbaxy Fine Chemicals Ltd., New Delhi.

1,1,3,3, tetraethoxypropane and reduced glutathione were from Sigma chemicals Co. St. Louis, MO, USA. 5, 5' dithiobis(2-nitrobenzoic acid) was from SRL Pvt. Ltd., Mumbai. Morin was from CDH Pvt. Ltd., New Delhi. Pure sample of gemcitabine used in present study was obtained from Parchem, New Rochelle, New York, USA. All other reagents were of analytical grade. Goat liver was used as the lipid source.

Preparation of tissue homogenate

Goat liver was collected from Silchar Municipal Corporation approved outlet. Goat liver was selected because of its easy availability and close similarity with human liver in its lipid profile¹⁰. Goat liver perfused with normal saline through hepatic portal vein was harvested and its lobes were briefly dried between filter papers to remove excess blood and thin cut with a heavy-duty blade. The small pieces were then transferred in a sterile vessel containing phosphate buffer (pH 7.4) solution. After draining the buffer solution as completely as possible, the liver was immediately grinded to make a tissue homogenate (1 g/ml) using freshly prepared phosphate buffer (pH 7.4). The homogenate was divided into four equal parts, which were then treated differently as mentioned below.

One portion of the homogenate was kept as control (C) while a second portion was treated with the gemcitabine (D) at a concentration of 1.2mg/g tissue homogenate. The third portion was treated with both gemcitabine at a concentration 1.2mg/g tissue homogenate and morin at a concentration of 0.1666 mg / g homogenate (DA) and the fourth portion was treated only with water extract of morin at a concentration of 0.1666 mg / g tissue homogenate (A). After gemcitabine and/or morin treatment, the liver tissue homogenate samples were shaken for two hours and the malondialdehyde and reduced glutathione content of various portions were determined.

Estimation of malondialdehyde (MDA) level from tissue homogenate

The extent of lipid peroxidation was measured in terms of malondialdehyde (MDA) content using thiobarbituric acid (TBA) method¹¹. The estimation was done at two hours of incubation and repeated in three animal sets. In each case three samples of 2.5 ml of incubation mixture were treated with 2.5 ml of 10% (w/v) trichloroacetic acid (TCA) and centrifuged at room temperature at 3000 rpm for 30 minutes to precipitate protein. Then 2.5 ml of the supernatant was treated with 5 ml of 0.002 (M) TBA solutions and then volume was made up to 10 ml with distilled water. The mixture was heated on a boiling water bath for 30 minutes. Then tubes were cooled to a room temperature and the absorbance was measured at 530 nm against a TBA blank (prepared from 5 ml of TBA solution and 5 ml of distilled water). The concentrations of MDA were determined from standard curve, which was constructed as follows. Different aliquots from standard 1, 1, 3, 3-tetrahydroxypropane (TEP) solution were taken in graduated stoppered test tubes and volume of each solution was made up to 5 ml. To each solution, 5 ml of TBA solution was added and the mixture was heated in a steam bath for 30 minutes. The solutions were cooled to a room temperature and their absorbances were measured at 530 nm against TBA as blank. By plotting absorbances against concentrations a straight line passing through the origin of grid was obtained. The best-fit equation is $A = 0.006776 M + 0.003467$, where M= nanomoles of MDA, A= absorbance, $r = 0.996$, $SEE = 0.0037$, $F = 1068.76$ ($df = 1,8$).

Estimation of reduced glutathione (GSH) level from tissue homogenate

The extent of lipid peroxidation was measured in terms of reduced glutathione level by Ellman's method¹². The estimation was done at two hours of incubation and repeated in three animal sets. In each case three samples of 1 ml of incubation mixture were treated with 1 ml of 5% (w/v) TCA in 1 mM EDTA centrifuged at 2000 g for 10 minutes. After that 1 ml of the filtrate was mixed with 5 ml of 0.1M phosphate buffer (pH 8.0) and 0.4 ml of 5, 5'-dithiobis(2-nitrobenzoic acid in 0.01% in phosphate buffer pH 8.0) (DTNB) was added to it. The absorbances of the solutions were measured at 412 nm against blank (prepared from 6.0 ml of phosphate buffer and 0.4 ml of DTNB) (0.01% in phosphate buffer). The concentrations of reduced glutathione were determined from standard curve, which was constructed as follows. Different aliquots from standard reduced glutathione solution were taken in 10.00 ml volumetric flask. To each solution 0.04 ml of DTNB solution was added and volume was adjusted up to the mark with phosphate buffer. The absorbances of each solution were noted at 412 nm against a blank containing 9.60 ml phosphate buffer and 0.04 ml DTNB solution. By plotting absorbances against concentrations a straight line passing through the origin was obtained. The best-fit equation is $A = 0.001536 M - 0.00695$, where M= nanomoles of GSH, A= absorbance, $r = 0.995$, $SEE = 0.0067$, $F = 1638.83$ ($df = 1,8$).

STATISTICAL ANALYSIS

Analysis of variance (ANOVA) and multiple comparison analysis using least significant different procedure¹³⁻¹⁴ were also performed on the percent changes data of various groups such as gemcitabine-treated (D), gemcitabine and morin (DA) and only morin-treated (A) with respect to control group of corresponding time.

Table 1: Effect of morin on gemcitabine induced lipid peroxidation: Changes in MDA profile

Hours of incubation	Animal sets	% Changes in MDA content			Analysis of variance & multiple comparison
		Samples			
		D	DA	A	
2	AL1	28.65 ^a	-13.71 ^a	-18.56 ^a	F1=1128.87 [df=(2,4)]
	AL2	29.37 ^a	-14.04 ^b	-20.88 ^b	F2=0.72 [df=(2, 4)]
	AL3	28.08 ^a	-12.84 ^a	-16.85 ^b	Pooled variance
					(S ²) [*] =1.79
	AV. (± S.E.)	28.70 (±0.37)	-13.53 (±0.35)	-18.76 (±1.16)	Critical difference,(p=0.05) [#] LSD =1.45 Ranked means** (D) (DA) (A)

% Changes with respect to controls of corresponding hours are shown: a>99%; b=97.5-99%; c=95-97.5%; d=90-95%; e=80-90%; f=70-80%; g=60-70%; h<60%; Theoretical values of F: p=0.05 level F1=6.94 [df=(2,4)], F2=6.94 [df=(2, 4)], F1 and F2 corresponding to variance ratio between groups and within groups respectively. D, DA, A indicate gemcitabine-treated, gemcitabine and morin-treated, morin-treated respectively. AV.= Averages of three animal sets; S.E.= Standard Error (df=2); df= degree of freedom; * Error mean square, # Critical difference according to least significant procedure¹⁴ ** Two means not included within same parenthesis are statistically significantly different at p=0.05 level

Table 2: Effect of morin on gemcitabine induced lipid peroxidation: Changes in GSH profile

Hours of incubation	Animal sets	% Changes in GSH content			Analysis of variance & multiple comparison
		Samples			
		D	DA	A	
2	AL1	-11.45 ^a	5.74 ^a	3.45 ^a	F1=44.81 [df=(2,4)]
	AL2	-13.23 ^b	9.89 ^a	6.61 ^a	F2=0.63 [df=(2, 4)]
	AL3	-15.94 ^a	13.20 ^b	9.35 ^a	Pooled variance
					(S ²)* =10.55
	AV. (± S.E.)	-13.54 (±1.30)	9.61 (±2.15)	6.47 (±1.70)	Critical difference,(p=0.05) [#] LSD =3.53 Ranked means** (D) (DA, A)

% Changes with respect to controls of corresponding hours are shown: a>99%; b=97.5-99%; c=95-97.5%; d=90-95%; e=80-90%; f=70-80%; g=60-70%; h<60%; Theoretical values of F: p=0.05 level F1=6.94 [df=(2,4)], F2=6.94 [df=(2, 4)], F1 and F2 corresponding to variance ratio between groups and within groups respectively. D, DA, A indicate gemcitabine-treated, gemcitabine and morin-treated, morin-treated respectively. AV.= Averages of three animal sets; S.E. = Standard Error (df=2); df= degree of freedom; * Error mean square, # Critical difference according to least significant procedure¹⁴ ** Two means not included within same parenthesis are statistically significantly different at p=0.05 level

RESULTS & DISCUSSION

The percent changes in MDA and GSH content of different samples at two hours of incubation were calculated with respect to the control of the corresponding time of incubation and was considered as indicator of the extent of lipid peroxidation.

From Table 1 it was evident that tissue homogenates treated with gemcitabine showed an increase in MDA (28.70 %) content in samples with respect to control at two hours of incubation to a significant extent. The observations suggest that gemcitabine could significantly induce the lipid peroxidation process. MDA is a highly reactive three-carbon dialdehyde produced as a byproduct of polyunsaturated fatty acid peroxidation and arachidonic acid metabolism¹⁵. But the MDA (-13.53 %) content were significantly reduced in comparison to gemcitabine-treated group when tissue homogenates were treated with gemcitabine in combination with morin. Again the tissue homogenates were treated only with the morin then the MDA (-18.76%) level were reduced in comparison to gemcitabine treated group. This decrease may be due to the free radical scavenging property of the morin. So the decrease in MDA content of samples, when treated with gemcitabine and morin implies the free radical scavenging property of morin.

It was also evident from Table 2 that tissue homogenates treated with gemcitabine showed a decrease in GSH (-13.54%) content in samples with respect to control to a significant extent. The observations suggest that gemcitabine could significantly induce the lipid peroxidation process. Glutathione is a small protein composed of three amino acid, such as cysteine, glutamic acid and glycine¹⁶. It is an important antioxidant and plays a very important role in the defence mechanism for tissue against the reactive oxygen species¹⁷. But the GSH content was significantly increased (9.61%) in comparison to control and gemcitabine-treated group when tissue homogenates were treated with gemcitabine in combination with morin. Again the tissue homogenates was treated only with morin then the GSH level was increased (6.47%) in comparison to the control and the gemcitabine treated group. This increase may be explained by the free radical scavenging property of the morin.

To compare means of more than two samples, multiple comparison analysis along with analysis of variance was performed on the percent changes data with respect to control of corresponding hours. It is seen that there is significant differences among various groups (F1) such as gemcitabine-treated, gemcitabine and morin-treated and only morin-treated. But within a particular group, differences (F2) are insignificant which

shows that there is no statistical difference in animals in a particular group (Tables 1 & 2). The Table 1 also indicates that for MDA content, gemcitabine-treated group, gemcitabine and morin-treated and only morin-treated groups are statistically significantly different from each other. From Table 2 it was observed that gemcitabine-treated group is statistically different from gemcitabine and morin-treated and only morin-treated groups, but there is no difference between gemcitabine and morin-treated and only morin-treated groups.

CONCLUSION

The findings of the work showed the lipid peroxidation induction potential of gemcitabine, which may be related to its toxic potential. The results also suggest the antiperoxidative effects of morin and demonstrate its potential to reduce gemcitabine induced toxic effects.

REFERENCES

1. Ray S. Evaluation of protective role of morin on busulfan-induced lipid peroxidation. *Inter J Pharm Tech Res* 2011; 3: 2222-7.
2. Ray S, Dey Ray S. Exploring protective role of morin on paclitaxel-induced lipid peroxidation using malondialdehyde and 4-hydroxy-2-nonenal as model markers. *Inter Res J Pharm* 2016; 7: 53-6.
3. Zhang XW, Ma YX, Sun Y, Cao YB, Li Q, Xu CA. Gemcitabine in Combination with a Second Cytotoxic Agent in the First-Line Treatment of Locally Advanced or Metastatic Pancreatic Cancer: a Systematic Review and Meta-Analysis. *Target Oncol* 2017; 12: 309-21.
4. Gutteridge, JMC, Halliwell B. Free radicals and antioxidants in the year 2000. A historical look to the future. *Ann N Y Aca Sci* 2000; 899: 136-47.
5. Stohs SJ. The role of free radicals in toxicity and disease. *J Basic Clin Physiol Pharmacol* 1995; 6: 205-28.
6. Romero RJ, BoschMorell F, Romero MJ, Jareno EJ, Romero B, Marin N, Roma J. Lipid peroxidation products and antioxidants in human disease. *Environ Health Perspect* 1998; 106: 1229-34.
7. Esterbauer H, Zollner H, Schauer RJ. Hydroalkenals: Cytotoxic products of lipid peroxidation. *Biochem Mol Biol* 1998; 1: 311-19.
8. Vendrely V, Peuchant E, Buscail E, Moravillier I, Rousseau B, Bedel A *et al.* Resveratrol and capsaicin used together as food complements reduce tumor growth and rescue full efficiency of low dose gemcitabine in a pancreatic cancer model. *Cancer Lett* 2017; 390: 390-91

9. Abu-Fayyad A, Nazzal S. Gemcitabine-vitamin E conjugates: Synthesis, characterization, entrapment into nanoemulsions, and in-vitro deamination and antitumor activity. *Inter J Pharm* 2017; 528: 463-70
10. Hilditch TP, Williams PN. *The Chemical Constituents of Fats*. London: Chapman & Hall; 1964.
11. Ohkawa H, Ohishi N, Yagi K. Assay of lipid peroxidation in animal tissue by thiobarbituric acid reaction. *Anal Biochem* 1979; 95: 351-58.
12. George E L. Tissue Sulfhydryl Groups, *Arch Biochem Biophys* 1959; 82: 70-7.
13. Snedecor GW, Cochran WG. *Statistical Methods*. New Delhi: Oxford & IBH Publishing Co Pvt Ltd; 1967.
14. Bolton S. Statistics. In: Gennaro AR, editor. *Remington: The Science and Practice of Pharmacy*. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 124-58.
15. Yahya MD, Pinnsa JL, Meinke GC, Lung CC. Antibodies against malondialdehyde (MDA) in MLR / lpr / lpr Mice: Evidence for an autoimmune mechanism involving lipid peroxidation. *J Autoimmun* 1996; 9: 3-9.
16. Benet L Z, Schwartz J B. In Goodman & Gilman's *The Pharmacological Basis of Therapeutics*. 9th ed. New York: Mc Graw- Hill; 1996. p. 707-16.
17. Wilkinson G R. In Goodman & Gilman's *The Pharmacological Basis of Therapeutics*. 10th ed. New York: Mc Graw- Hill; 2001. p. 10-20.

Cite this article as:

Sarbani Dey Ray. Estimation of gemcitabine-induced lipid peroxidation using common laboratory markers: Role of morin. *Int. Res. J. Pharm.* 2018;9(6):138-141 <http://dx.doi.org/10.7897/2230-8407.096105>

Source of support: Nil, Conflict of interest: None Declared

Disclaimer: IRJP is solely owned by Moksha Publishing House - A non-profit publishing house, dedicated to publish quality research, while every effort has been taken to verify the accuracy of the content published in our Journal. IRJP cannot accept any responsibility or liability for the site content and articles published. The views expressed in articles by our contributing authors are not necessarily those of IRJP editor or editorial board members.